A R T I C L E S
Hamada et al.
737, 694; [R]20Na +5.39 (c 10.0, CHCl3); MS(EI), m/z 347[M]+; Anal.
Calcd for C23H25NO: C, 82.95; H, 8.41. Found; C, 82.73; H, 8.54.
(R)-(+)-2-Methyl-2-(o-tolyl)-5-(N-methylanilinomethylene)cyclo-
+22.9 (c 10.0, CHCl3); MS(EI), m/z 363[M]+; Anal. Calcd for C23H25-
NO3: C, 82.95; H, 8.41. Found; C, 82.73; H, 8.54.
(R)-(+)-2-Propyl-2-(m-tolyl)-5-(N-methyl-anilinomethylene)cyclo-
1
1
pentanone (2b). H NMR (300 MHz, CDCl3) δ 7.65 (t, J ) 1.5 Hz,
pentanone (2i). H NMR (300 MHz, CDCl3) δ 7.59 (s, 1H), 7.33-
1H), 7.38-7.32 (m, 3 H), 7.17-7.12 (m, 6H), 3.53 (s, 3H), 2.63-
2.55 (m, 2H), 2.26 (s, 3H), 2.25-2.16 (m, 1H), 1.85-1.76 (m, 1H),
1.51 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 208.6, 146.3, 143.0, 136.5,
132.1, 129.3, 129.1, 127.6, 126.7, 125.7, 124.9, 121.7, 107.7, 53.5,
6.99 (m, 9H), 3.43 (s, 3H), 2.56-2.37 (m, 3H), 2.33 (s, 3H), 2.01-
1.82 (m, 2H), 1.67-1.57 (m, 1H), 1.21-1.03 (m, 2H), 0.83 (t, J ) 7.2
Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 206.7, 146.3, 142.2, 141,5,
137.7, 129.1, 128.1, 127.7, 127.1, 124.6, 123.8, 121.1, 108.6, 56.3,
41.8, 40.0, 32.5, 25.2, 21.9, 18.4, 14.9; IR (neat, cm-1) 2956, 2931,
2871, 1686, 1567, 885, 773, 731; [R]20Na +28.4 (c 10.0, CHCl3); MS-
(EI), m/z 333[M]+, Anal. Calcd for C23H27NO: C, 82.84; H, 8.16.
Found; C, 82.91; H, 8.30.
40.7, 36.5, 25.1, 23.8, 22.5; IR(neat, cm-1) 2964, 1684, 1567, [R]20
Na
+29.3 (c 1.2, CHCl3); MS(EI), m/z 305[M]+, Anal. Calcd for C21H23-
NO: C, 82.58; H, 7.59. Found; C, 82.53; H, 7.68.
(R)-(+)-2-Methyl-2-(m-tolyl)-5-(N-methylanilinomethylene)cyclo-
1
pentanone (2c). H NMR (300 MHz, CDCl3) δ 7.64 (t, J ) 1.5 Hz,
(R)-(+)-2-Pentyl-2-(m-tolyl)-5-(N-methyl-anilinomethylene)cyclo-
1H), 7.34-7.29 (m, 2H), 7.19-7.09 (m, 6H), 7.02-6.98 (m, 1H), 3.47
(s, 3H), 2.51-2.33 (m, 3H), 2.32 (s, 3H), 1.90-1.81 (m, 1H), 1.43 (s,
3H);13C NMR (75 MHz, CDCl3) δ 207.6, 146.2, 144.2, 142.6, 137.8,
129.2, 128.2, 127.3, 127.0, 124.7, 123.4, 121.3, 108.3, 52.7, 40.2, 36.9,
25.4, 25.1, 21.9; IR (neat, cm-1) 2960, 2932, 2863, 1686, 1563, 920,
1
pentanone (2j). H NMR (300 MHz, CDCl3) δ 7.58 (s, 1H), 7.31-
6.98 (m, 9H), 3.44 (s, 3H), 2.56-2.43 (m, 3H), 2.32 (s, 3H), 2.02-
1.83 (m, 2H), 1.70-1.60 (m, 1H), 1.20-1.02 (m, 6H), 0.81 (t, J ) 6.6
Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 206.6, 146.2, 142.1, 141.5,
137.6, 129.1, 128.0, 127.6, 127.0, 124.5, 123.7, 121.0, 108.6, 56.2,
39.9, 39.4, 32.6, 32.6, 25.1, 24.6, 22.7, 21.9, 14.3; IR(neat) 2954, 2931,
2858, 1686, 1567, 908, 754, 710; [R]25Na +35.4 (c 10.0, CHCl3); MS-
(EI), m/z 361[M]+, Anal. Calcd for C25H31NO: C, 83.06; H, 8.64.
Found; C, 82.81; H, 8.66.
787, 754, 696; [R]20 +9.37 (c 10.0, CHCl3); MS(EI), m/z 305[M]+;
Na
Anal. Calcd for C21H23NO: C, 82.58; H, 7.59. Found; C, 82.40; H,
7.70.
(R)-(+)-2-Methyl-2-(p-tolyl)-5-(N-methyl-anilinomethylene)cyclo-
1
pentanone (2d). H NMR (300 MHz, CDCl3) δ 7.63 (t, J ) 1.5 Hz,
(R)-(+)-2-Methyl-2-phenyl-5-(N-methyl-anilinomethylene)cyclo-
1H), 7.34-7.24 (m, 4H), 7.14-7.08 (m, 5H), 3.47 (s, 3H), 2.51-2.34
(m, 3H), 2.30 (s, 3H), 1.90-1.80 (m, 1H), 1.41 (s, 3H); 13C NMR (75
MHz, CDCl3) δ 207.6, 146.2, 142.5, 141.2, 135.8, 129.2, 129.1, 126.5,
1
pentanone (2k). H NMR (300 MHz, CDCl3) δ 7.64 (t, J ) 1.5 Hz,
1H), 7.40-7.09 (m, 10H), 3.47 (s, 3H), 2.52-2.37 (m, 3H), 1.93-
1.82 (m, 1H), 1.44 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 207.6, 146.2,
144.3, 142.8, 129.2, 128.4, 126.5, 126.3, 124.9, 121.4, 108.2, 52.7,
40.4, 36.9, 25.3, 25.0; IR (neat, cm-1) 2957, 2862, 1683, 1602, 1569,
124.7, 121.3, 108.3, 52.4, 40.2, 36.7, 25.4, 25.0, 21.2; IR (neat, cm-1
)
2958, 2923, 2863, 1688, 1605, 1563, 920, 818, 802, 754, 694; [R]20
Na
+5.41 (c 10.0, CHCl3); MS(EI), m/z 305[M]+; Anal. Calcd for C23H25-
NO3: C, 82.95; H, 8.41. Found; C, 82.73; H, 8.54, Anal. Calcd for
C21H23NO: C, 82.58; H, 7.59. Found; C, 82.56; H, 7.58.
923, 756, 697; [R]20 +20.0 (c 5.83, CHCl3); MS(EI), m/z 291[M]+;
Na
Anal. Calcd for C20H21NO: C, 82.44; H, 7.26. Found; C, 82.20; H,
(R)-(+)-2-Methyl-2-(m-anisyl)-5-(N-methyl-anilinomethylene)cy-
clopentanone (2e). 1H NMR (300 MHz, CDCl3) δ 7.63 (s, 1H), 7.34-
6.95 (m, 8H), 6.75-6.71 (m, 1H), 3.78 (s, 3H), 3.45 (s, 3H), 2.49-
2.34 (m, 3H), 1.90-1.81 (m, 1H), 1.43 (s, 3H); 13C NMR (75 MHz,
CDCl3) δ 207.2, 159.5, 146.1, 145.9, 142.6, 129.2, 129.1, 124.7, 121.3,
118.9, 112.8, 111.3, 108.1, 55.3, 52.7, 40.2, 36.8, 25.3, 25.0; IR (neat,
cm-1) 2960, 2863, 1686, 1561, 920, 895, 781, 739, 694; [R]20Na +0.30
(c 10.0, CHCl3); MS(EI), m/z 321[M]+; Anal. Calcd for C21H23NO2:
C, 78.47; H, 7.21. Found; C, 78.22; H, 7.22.
7.24.
Procedure for Removing the Blocking Group.16 Ketone 2k (84
mg, 0.29 mmol) was dissolved in THF (8.0 mL) in a round-bottomed
flask. Aqueous HCl (1 M, 6.0 mL) was added and the mixture stirred
at room temperature until 2k had been completely consumed, as judged
by GC analysis (ca. 3 h). The mixture was diluted with water (10 mL)
and ether (10 mL) and was poured into a separatory funnel; the layers
were then separated. The aqueous layer was extracted with ether (10
mL), and the organic layers were combined and concentrated in vacuo.
The residual oil was dissolved in aqueous NaOH solution (1 M, 8 mL)
in a round-bottomed flask equipped with a reflux condenser, and the
resulting solution was stirred at 90 °C for 2 h. The mixture was cooled
to room temperature, neutralized with aqueous HCl (1 M), and diluted
with ether (20 mL). The mixture was poured into a separatory funnel,
and the layers were separated. The aqueous layer was extracted with
ether (10 mL), and the combined organic layers were washed with brine
(10 mL), dried over MgSO4, filtered, and concentrated in vacuo. The
crude material was purified by flash chromatography on silica gel to
give (R)-(+)-2-methyl-2-phenylcyclopentanone 522 (46.0 mg, 91%,
(R)-(+)-2-Methyl-2-(p-anisyl)-5-(N-methyl-anilinomethylene)cy-
clopentanone (2f). 1H NMR (300 MHz, CDCl3) δ 7.62 (t, J ) 1.5 Hz,
1H), 7.33-7.29 (m, 4 H), 7.13-7.08 (m, 3H), 6.85-6.80 (m, 2H),
3.75 (s, 3H), 3.45 (s, 3H), 2.56-2.32 (m, 3H), 1.89-1.79 (m, 1H),
1.41 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 207.5, 157.8, 146.1, 142.4,
136.1, 129.1, 127.4, 124.6, 121.1, 113.6, 108.0, 55.3, 51.9, 40.1, 36.6,
25.4, 24.9; IR (neat, cm-1) 2960, 2836, 1684, 1561 920, 860, 802,
729, 694; [R]20Na +1.53 (c 10.0, CHCl3); MS(EI), m/z 321[M]+; Anal.
Calcd for C21H23NO: C, 82.58; H, 7.59. Found; C, 82.53; H, 7.68.
(R)-(+)-2-Methyl-2-(p-trifluoromethanephenyl)-5-(N-methyl-anili-
1
nomethylene)cyclopentanone (2 g). H NMR (300 MHz, CDCl3) δ
[R]20 +76.6 (c 3.4, EtOH), 93% ee) as a colorless oil.
Na
7.65 (s, 1H), 7.55-7.49 (m, 4H), 7.35-7.30 (m, 2H), 7.16-7.10 (m,
3H), 3.48 (s, 3H), 2.56-2.30 (m, 3H), 1.97-1.87 (m, 1H), 1.45 (m,
3H); 13C NMR (75 MHz, CDCl3) δ 206.4, 148.7, 145.9, 143.3, 128.2,
128.5, 128.1, 127.0, 126.1, 125.2, 125.1, 125.0, 122.5, 121.6, 107.3,
Acknowledgment. This research was funded by the National
Institutes of Health (GM46059) with additional support from
Ajinomoto Co., Inc. We are grateful to Drs. Joseph M. Fox
and Alex R. Muci for helpful discussions as well as assistance
in the preparation of the manuscript.
52.7, 40.5, 36.7, 25.0, 24.8; IR(neat, cm-1) 2964, 1686, 1565; [R]20
Na
+7.7 (c 10.0, CHCl3); MS(EI), m/z 359[M]+, Anal. Calcd for C21H20-
NOF3: C, 70.18; H, 5.61. Found; C, 69.89, H, 5.47.
(R)-(+)-2-(3-[1,3]Dioxolan-2-yl-phenyl)-2-methyl-5-(N-methyl-
anilinomethylene)cyclopentanone (2h). 1H NMR (300 MHz, CDCl3)
δ 7.63 (s, 1H), 7.49 (s, 1H), 7.42-7.27 (m, 4H), 7.14-7.08 (m, 3H),
5.78 (s, 1H), 4.14-3.98 (m, 3H), 3.46 (s, 3H), 2.55-2.37 (m, 3H),
1.92-1.83 (m, 1H), 1.43 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 207.1,
146.1, 144.4, 142.7, 141.2, 137.6, 129.3, 129.1, 128.4, 127.6, 124.8,
124.7, 121.4, 108.1, 104.0, 65.4, 52.4, 40.3, 36.7, 25.4, 25.0; IR (neat,
Supporting Information Available: 1H and 31P NMR spectra
of 4a and 4h, and additional results in the arylation of 1a with
other commercially available ligands and reactions with different
aryl halides using 3/Pd-based catalysts (PDF). This material is
cm-1) 2960, 2927, 2887, 1684, 1605, 1565, 920, 802, 756, 696; [R]20
JA011122+
Na
9
1268 J. AM. CHEM. SOC. VOL. 124, NO. 7, 2002